Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NYSE]
Sanofi
Index- P/E21.25 EPS (ttm)1.89 Insider Own16.40% Shs Outstand2.49B Perf Week1.90%
Market Cap100.25B Forward P/E12.70 EPS next Y3.17 Insider Trans0.00% Shs Float2.30B Perf Month-5.46%
Income4.97B PEG2.99 EPS next Q0.75 Inst Own9.70% Short Float0.22% Perf Quarter7.33%
Sales38.72B P/S2.59 EPS this Y4.10% Inst Trans-0.03% Short Ratio2.57 Perf Half Y-5.18%
Book/sh25.36 P/B1.59 EPS next Y0.16% ROA- Target Price52.00 Perf Year-14.99%
Cash/sh- P/C- EPS next 5Y7.10% ROE- 52W Range36.11 - 52.76 Perf YTD-1.76%
Dividend1.63 P/FCF- EPS past 5Y-4.40% ROI6.50% 52W High-23.79% Beta0.99
Dividend %4.05% Quick Ratio- Sales past 5Y0.50% Gross Margin68.80% 52W Low11.35% ATR0.69
Employees115631 Current Ratio- Sales Q/Q-3.60% Oper. Margin- RSI (14)55.09 Volatility1.24% 1.30%
OptionableYes Debt/Eq- EPS Q/Q4.60% Profit Margin- Rel Volume0.69 Prev Close39.53
ShortableYes LT Debt/Eq- EarningsApr 29 BMO Payout- Avg Volume2.01M Price40.21
Recom2.30 SMA201.15% SMA500.66% SMA200-5.35% Volume1,404,000 Change1.72%
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
May-25-16 01:00AM  Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis Business Wire
12:37AM  Exclusive: Sanofi to unveil challenge to Medivation's board - sources
May-24-16 03:06PM  Sanofis Diabetes and Cardiovascular Franchise Performance
12:24PM  Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why at Motley Fool
11:53AM  Allergan, Inc. (AGN) Receives Good News from Japan at Insider Monkey
11:07AM  How Does Merial Contribute to Sanofis Growth?
11:02AM  New Cholesterol Treatment Now Available for Canadians PR Newswire
08:07AM  Sanofi Diabetes Drugs Briefing Documents Raise Concerns
May-23-16 01:05PM  FDA staff question usefulness of Sanofi diabetes drugs Reuters
12:52PM  Rlypsa Stock Pops on New Data and a Huge Risk
12:02PM  Behind the Worlds Top Drugmakers Approach to Zika Vaccine at Bloomberg
09:18AM  FDA Staff Questions Usefulness of Sanofis Diabetes Drug Combo at Bloomberg
08:49AM  FDA staff question dosing of Sanofi combination diabetes drug Reuters
May-20-16 09:30AM  The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
May-19-16 03:46PM  Genzyme Continues Driving Growth for Sanofi
03:46PM  Sanofis Growth Drivers for 1Q16
03:45PM  A Peek at Sanofis Valuation Cheat Sheet
03:36PM  Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
May-18-16 10:44AM  Warren Buffett Owns These 3 High-Yield Dividend Stocks -- Shouldn't You? at TheStreet
May-17-16 04:22PM  Inovio Pharmaceuticals' Zika Vaccine Takes a Big Step Forward at Motley Fool
12:38PM  ALK appoints Carsten Hellmann as new President and CEO GlobeNewswire
May-16-16 06:07PM  Regeneron Pharmaceuticals Collaboration Revenue in 1Q16
01:14PM  Pfizer to buy Peninsula drug developer for $5.2 billion in latest Bay Area M&A at American City Business Journals
11:05AM  Sanofi Genzyme doubles down on recent success in multiple sclerosis at bizjournals.com
09:00AM  Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine Business Wire
May-14-16 12:01AM  [$$] Regeneron: The Best Bet in Biotech Stocks at Barrons.com
May-13-16 06:07PM  Medivation Is for Sale: How Much Should It Get?
05:46PM  Medivation Shares Stand Pat Amid Further Bid Speculation at TheStreet
11:55AM  Sanofi presses on with threat to oust Medivation's board Reuters
10:45AM  Sanofi Said to Nominate Slate to Replace Medivation Board at Bloomberg
May-12-16 09:35AM  Analyzing Medivations Growth Opportunity with Xtandi Market Realist
May-11-16 02:00PM  Ex-FDA head and Sanofi call for harmonised drug regulation Reuters
May-10-16 04:13PM  Why Did Medivations Share Price Increase so Much after Earnings? Market Realist
02:54PM  Ionis Pharmaceuticals Inc Is Burning Partners' Cash (Thank Goodness There's Lots of It) at Motley Fool
01:42PM  Here's Why MannKind Corporation is Down Big Today at Motley Fool
06:29AM  Why Amicus Therapeutics, Inc. Stock Slumped 14.0% in April at Motley Fool
May-09-16 04:32PM  Medivation Reportedly Yielding To Buyer Interest; Stock Surges at Investor's Business Daily
02:15PM  Exclusive: Medivation succumbs to pressure to explore sale -sources Reuters
02:00PM  Medivation (MDVN) Stock Surges, Will Explore Sale at TheStreet
May-08-16 09:49PM  DODFX: Dodge & Cox International Top 5 Holdings Analysis at Investopedia
06:48PM  Startling Disclosure in Relypsa's Filings Reveal a Possible Sanofi Takeover Yahoo Finance Contributors
May-06-16 06:08PM  Biz Break: Yelp gets strong recommendations after results at San Jose Mercury News
02:40PM  Medivation appeals to its 'great teams' of employees in Sanofi saga. But how long can it repel buyer? at American City Business Journals
01:41PM  Why MannKind Corporation's Stock Plunged 15.1% in April at Motley Fool
12:03PM  Why These Five Stocks Are Trending Today? at Insider Monkey
10:41AM  Medivation: Better On Its Own? at Barrons.com
10:07AM  U.S. stocks extend losses after disappointing jobs report at MarketWatch
08:04AM  Medivation Takeover Talk: Sanofi May Lose Out Despite Offer To Raise Bid Yahoo Finance Contributors
07:26AM  Sanofi's Medivation Bear Hug Lacks Muscle at Bloomberg
12:07AM  [$$] Sanofi Says It Will Try to Oust Medivation Board Members if Deal Talks Dont Start at The Wall Street Journal
May-05-16 07:41PM  Sanofi ready to up offer for drugmaker Medivation, could oust board Reuters
07:36PM  [$$] Sanofi: Will Try to Oust Medivation Board Unless Deal Talks Start at The Wall Street Journal
07:01PM  Sanofi, Amgen Set to Get U.K. Access for Drugs With Discount at Bloomberg
07:01PM  Sanofi, Amgen cholesterol drugs win UK backing after price cuts Reuters
05:01PM  Medivation Misses Q1 Estimates As Sanofi Turns Up The Buyout Heat at Investor's Business Daily
04:58PM  As Sanofi hints at higher takeover price, Medivation holds its ground at American City Business Journals
04:48PM  Medivation: And Then There Were Five at Barrons.com
01:30PM  Global Business Report: Sanofi, Alibaba, Disney in China Bloomberg
01:22PM  [$$] Regeneron Raises Sales Expectations for Eylea at The Wall Street Journal
01:21PM  Medivation Reiterates Rejection Of Sanofi's Inadequate Proposal To Buy It Benzinga
01:09PM  Medivation Rejects Sanofi Bid Again, Calling It `Opportunistic' at Bloomberg
12:52PM  Sanofi presses drugmaker Medivation to take $9.3B offer AP
12:30PM  [$$] Sanofi threatens to go hostile in $9.3bn pursuit of Medivation at Financial Times
11:26AM  Sanofi Threatens to go Hostile in Medivation Battle at TheStreet
10:42AM  Regeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View Zacks
10:20AM  Ionis Incurs Wider-than-Expected Loss in Q1, Stock Down Zacks
10:09AM  Regeneron Pharmaceuticals: The Eyleas Have It at Barrons.com
09:25AM  Why Medivation is such an attractive acquisition target Yahoo Finance Contributors
08:36AM  Sanofi Urges Medivation to Join Talks on $9.3 Billion Offer at Bloomberg
May-04-16 05:03PM  Interest Rises in Medivation Oncology Prospects at TheStreet
04:38PM  ETFs with exposure to Sanofi : May 4, 2016 at Capital Cube
03:38PM  Medivation rises amid possible Pfizer takeover bid at CNBC
02:08PM  Sanofi sees "strong strategic" fit with U.S. Medivation Reuters
01:26PM  Pfizer eyes this San Francisco biotech involved in tight acquisition war at American City Business Journals
01:08PM  Will a Third Medivation Suitor Present Itself? at TheStreet
12:57PM  Medivation (MDVN) Stock Climbs on Potential Pfizer Deal at TheStreet
10:39AM  Sanofi says sees 'strong strategic' fit with Medivation Reuters
10:16AM  Sanofi says sees "strong strategic" fit with U.S. cancer firm Medivation Reuters
10:11AM  Who Will Win Medivation: Pfizer or Sanofi? Yahoo Finance Contributors
09:07AM  A Look at Vertexs Cystic Fibrosis Patient Opportunity Market Realist
May-03-16 06:33PM  Forget Allergan: Pfizer Has Its Sights On This Cancer Drugmaker at Investor's Business Daily
06:28PM  Relypsa Taps Debt Market: Yeah, Thats Bullish Yahoo Finance Contributors
06:04PM  Exclusive: Pfizer approaches Medivation about potential takeover - sources Reuters
05:41PM  What Sent Medivation, Inc.'s Shares Soaring 25.1% In April at Motley Fool
05:38PM  Baby Powder Cancer Suits Cloud Johnson and Johnson Zacks
05:12PM  Regeneron Pharmaceuticals Inc Has a Lot to Prove on May 5 at Motley Fool
02:30PM  Hulu Takes Aim at DISH and Sony in Live Streaming at Investopedia
11:53AM  Medivation: Sanofi's Bid 'Significantly Undervaluing' Pipeline at Barrons.com
10:41AM  FEZ: An ETF Performance Case Study at Investopedia
10:34AM  Sanofi :SNY-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
07:05AM  Sanofi downgraded by HSBC Securities Briefing.com
May-02-16 11:28AM  Medivation: Why a Takeover Just Got a Little Tougher at Barrons.com
May-01-16 01:09PM  The Next Stock Warren Buffett May Sell at Motley Fool
Apr-29-16 09:20PM  DODFX: Dodge & Cox International Stock Fund Performance Case Study at Investopedia
07:08PM  [$$] Sanofi Seeks Talks With Medivation Over $9.3 Billion Offer at The Wall Street Journal
05:22PM  Worst may be over for embattled pharma Yahoo Finance Contributors
02:38PM  Here's What Medivation Said In Its Rejection Letter To Sanofi Benzinga
01:10PM  Why These Five Stocks Are on the Move Today? at Insider Monkey
12:30PM  AstraZeneca, Pfizer Said Among Firms Weighing Medivation Bid at Bloomberg
11:50AM  Medivation's Right to Play Hard-To-Get at Bloomberg
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerFeb 17Buy393.7180,00031,496,72823,353,665Feb 18 05:45 PM
Sanofi10% OwnerFeb 16Buy391.2381,15731,751,18223,273,665Feb 18 05:45 PM
Sanofi10% OwnerJan 12Buy465.0483,93839,034,66023,192,508Jan 14 05:46 PM
Sanofi10% OwnerNov 03Buy10.00900,0009,000,0003,218,899Nov 05 02:37 PM
Sanofi10% OwnerOct 06Buy472.3311,0405,214,51923,108,570Oct 08 05:50 PM
Sanofi10% OwnerOct 06Buy459.7180,53837,024,19723,097,530Oct 08 05:45 PM
Sanofi10% OwnerJul 27Buy537.4810,6395,718,27222,869,783Jul 29 05:46 PM